Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.53 |
| ▸ | CETP | P11597 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14020667 | 0.88 | CETP (0.58) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL16744155 | 0.80 | TLR2 (0.56) | TP53TLR2CASP3 | |
| SCHEMBL16744157 | 0.80 | TLR2 (0.56) | TP53TLR2CASP3 | |
| SCHEMBL16744156 | 0.80 | TLR2 (0.56) | TP53TLR2CASP3 | |
| SCHEMBL16744154 | 0.79 | TLR2 (0.54) | TP53TLR2CASP3 | |
| SCHEMBL27081834 | 0.79 | CASP3 (0.52) | TP53CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15087402 | 0.78 | KMT2A (0.51) | TP53KMT2ACASP3 | |
| SCHEMBL20371129 | 0.78 | KMT2A (0.51) | TP53KMT2ACASP3 | |
| SCHEMBL31105883 | 0.78 | MAPT (0.70) | TP53CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL15960134 | 0.77 | KMT2A (0.52) | TP53KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116331-A1 | Glycosylceramide analogues | BIOMIRA, INC. (CA) | 2006-06-01 | — | — | US | disclosed |
| EP-1572114-A2 | GLYCOSYLCERAMIDE ANALOGUES | BIOMIRA, INC. (CA) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004028475-A2 | GLYCOSYLCERAMIDE ANALOGUES | BIOMIRA, INC. (CA) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116331-A1 | Glycosylceramide analogues | UGCG, ASAH2, GBA2 | TP53 520/4885CYP1A2 4249/4885CYP2D6 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.